The PREDICT-RT study stratifies enrolled patients with high-risk cancer by Decipher Risk Score. Decipher testing was conducted by Veracyte, Inc. (VCYT), a global diagnostics company that provides high ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene ...

Findings published in European Urology Oncology suggest genomic classifier scores are highly correlated with PSMA PET upstaging of prostate cancer in those with high-risk and very high-risk disease ...

“This is an important study that provides further evidence for Decipher Prostate and demonstrates how this test could help physicians better personalize treatment for their patients with ...

With its range of products, Veracyte displays a robust and diverse portfolio, targeting multiple areas in oncology. Veracyte's recent data underscores the company's innovative edge in the field of ...

SAN DIEGO, Feb. 18, 2020 /PRNewswire/ -- Decipher Biosciences, a commercial-stage precision oncology company committed to improving patient care, initially focused on urologic cancers, today announced ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 17 Decipher-focused abstracts will be presented at the ...

Veracyte, Inc. VCYT shares are volatile after-hours on Wednesday after the company announced that new data from a phase 3 trial validates the value of the Decipher Prostate Genomic Classifier in ...

Germline correlates of clinical outcomes in aggressive prostate cancer subtypes treated with radiation therapy. Targeting highly aggressive ductal prostate tumours with poly ADP ribose polymerase ...

Veracyte Inc. reported new data showing its Decipher Prostate genomic classifier can help to identify patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who are more likely to ...

Veracyte (VCYT) is back in focus after announcing that more than 15 Decipher Bladder and Prostate studies will be presented at the 2026 American Urological Association Annual Meeting, highlighting ...